SI2718434T1 - Compositions and methods for treating celiac sprue disease - Google Patents

Compositions and methods for treating celiac sprue disease Download PDF

Info

Publication number
SI2718434T1
SI2718434T1 SI201231269T SI201231269T SI2718434T1 SI 2718434 T1 SI2718434 T1 SI 2718434T1 SI 201231269 T SI201231269 T SI 201231269T SI 201231269 T SI201231269 T SI 201231269T SI 2718434 T1 SI2718434 T1 SI 2718434T1
Authority
SI
Slovenia
Prior art keywords
seq
amino acid
polypeptide
acid sequence
residue
Prior art date
Application number
SI201231269T
Other languages
English (en)
Slovenian (sl)
Inventor
Justin Siegel
David Baker
Sydney Rin Anna Gordon
Ingrid Swanson Pultz
Elizabeth Joy Stanley
Sarah Jane Wolf
Original Assignee
University Of Washington Through Its Center For Commercialization
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Washington Through Its Center For Commercialization filed Critical University Of Washington Through Its Center For Commercialization
Publication of SI2718434T1 publication Critical patent/SI2718434T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Peptides Or Proteins (AREA)
SI201231269T 2011-08-10 2012-08-10 Compositions and methods for treating celiac sprue disease SI2718434T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161521899P 2011-08-10 2011-08-10
PCT/US2012/050364 WO2013023151A2 (en) 2011-08-10 2012-08-10 Compositions and methods for treating celiac sprue disease
EP12748354.3A EP2718434B1 (en) 2011-08-10 2012-08-10 Compositions and methods for treating celiac sprue disease

Publications (1)

Publication Number Publication Date
SI2718434T1 true SI2718434T1 (en) 2018-06-29

Family

ID=46690751

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201231269T SI2718434T1 (en) 2011-08-10 2012-08-10 Compositions and methods for treating celiac sprue disease

Country Status (18)

Country Link
US (7) US9289473B2 (show.php)
EP (3) EP3400958B1 (show.php)
JP (5) JP6342802B2 (show.php)
CA (1) CA2882502A1 (show.php)
CY (1) CY1120877T1 (show.php)
DK (1) DK2718434T3 (show.php)
ES (2) ES2896489T3 (show.php)
HR (1) HRP20180687T1 (show.php)
HU (1) HUE037870T2 (show.php)
LT (1) LT2718434T (show.php)
NO (1) NO2718434T3 (show.php)
PL (2) PL3400958T3 (show.php)
PT (1) PT2718434T (show.php)
RS (1) RS57234B1 (show.php)
SI (1) SI2718434T1 (show.php)
SM (1) SMT201800249T1 (show.php)
TR (1) TR201806885T4 (show.php)
WO (1) WO2013023151A2 (show.php)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6342802B2 (ja) 2011-08-10 2018-06-13 ザ ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャライゼーションＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｗａｓｈｉｎｇｔｏｎ Ｔｈｒｏｕｇｈ Ｉｔｓ Ｃｅｎｔｅｒ Ｆｏｒ Ｃｏｍｍｅｒｃｉａｌｉｚａｔｉｏｎ セリアックスプルー病を治療するための組成物および方法
EP3033100B1 (en) 2013-08-14 2018-10-03 University Of Washington Through Its Center For Commercialization Compositions for treating celiac sprue disease
EP3081942A1 (en) * 2015-04-17 2016-10-19 Roche Diagniostics GmbH Pressure transmission liquid for cellular analyzer, cellular analyzer and method for analyzing a liquid cellular sample
KR102702879B1 (ko) * 2015-06-08 2024-09-04 유니버시티 오브 워싱턴 셀리악 스프루 질환 치료용 조성물 및 방법
KR102553627B1 (ko) * 2016-12-22 2023-07-07 에베 누트리찌온 게엠베하 안정한 프로테아제 변이체
US20240226248A9 (en) * 2018-10-26 2024-07-11 The Regents Of The University Of California Methods and compositions for improving protein hydrolysis
US20200383351A1 (en) * 2018-10-26 2020-12-10 The Regents Of The University Of California Use of proteolytic enzymes to enhance protein bioavailability
CA3195929A1 (en) 2020-10-30 2022-05-05 Ingrid Swanson Pultz Compositions and methods for treating celiac sprue disease
CA3250056A1 (en) 2022-01-26 2023-08-03 Digestiva, Inc. METHODS AND COMPOSITIONS FOR BLOOD GLUCOSE STABILIZATION
WO2025068987A1 (en) 2023-09-28 2025-04-03 Takeda Pharmaceutical Company Limited A method of producing a kumamolisin-as polypeptide

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2688229B1 (fr) 1992-03-09 1995-06-23 Ulice Soc Procede de synthese enzymatique d'esters alkyliques de peptides, produits ainsi obtenus et utilisation desdits produits.
JP2002078489A (ja) * 2000-09-04 2002-03-19 Daiwa Kasei Kk セリン残基が活性発現に関与する新規酸性プロテアーゼ
US7320788B2 (en) * 2002-02-14 2008-01-22 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for Celiac Sprue
DE60336754D1 (de) 2002-02-14 2011-05-26 Univ R Enzymbehandlung von nahrungsmitteln für zöliakie-sprue
US8143210B2 (en) 2002-02-14 2012-03-27 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for celiac sprue
US7462688B2 (en) 2002-05-14 2008-12-09 The Board Of Trustees Of The Leland Stanford Junior University Peptides for diagnostic and therapeutic methods for celiac sprue
US7605150B2 (en) 2002-05-14 2009-10-20 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for Celiac Sprue
US7202216B2 (en) 2002-05-14 2007-04-10 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
US7265093B2 (en) 2002-05-14 2007-09-04 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for Celiac Sprue
ES2383595T3 (es) 2002-11-20 2012-06-22 The Board Of Trustees Of The Leland Stanford Junior University Procedimiento de diagnóstico de la celiaquía
US7579313B2 (en) 2003-11-18 2009-08-25 The Board Of Trustees Of The Leland Stanford Junior University Transglutaminase inhibitors and methods of use thereof
US7563864B2 (en) 2004-04-26 2009-07-21 Celiac Sprue Research Foundation Prolyl endopeptidase mediated destruction of T cell epitopes in whole gluten
US7534426B2 (en) 2004-04-26 2009-05-19 The Board Of Trustees Of The Leland Stanford Junior University Glutenase enzyme assays
US7628985B2 (en) 2004-04-26 2009-12-08 The Board Of Regents Of The Leland Stanford Junior University Therapeutic enzyme formulations and uses thereof in celiac sprue and/or dermatitis herpetoformis
EP1600141B1 (en) 2004-05-24 2013-04-17 3M Deutschland GmbH Collagenolytic active enzyme containing compositions for the treatment of dental caries
EP1726643A1 (en) * 2005-05-27 2006-11-29 Direvo Biotech AG Method for the provision, identification and selection of proteases with altered sensitivity to activity-modulating substances
JP2012500263A (ja) 2008-08-21 2012-01-05 アルヴィン ファーマシューティカルズ インコーポレーティッド タンパク質の経口投与のための製剤
JP6342802B2 (ja) 2011-08-10 2018-06-13 ザ ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャライゼーションＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｗａｓｈｉｎｇｔｏｎ Ｔｈｒｏｕｇｈ Ｉｔｓ Ｃｅｎｔｅｒ Ｆｏｒ Ｃｏｍｍｅｒｃｉａｌｉｚａｔｉｏｎ セリアックスプルー病を治療するための組成物および方法
IN2014CN04131A (show.php) 2011-12-06 2015-07-17 Fond Istituto Insubrico Di Ricerca Per La Vita
EP3033100B1 (en) 2013-08-14 2018-10-03 University Of Washington Through Its Center For Commercialization Compositions for treating celiac sprue disease
KR102702879B1 (ko) 2015-06-08 2024-09-04 유니버시티 오브 워싱턴 셀리악 스프루 질환 치료용 조성물 및 방법

Also Published As

Publication number Publication date
JP2021094031A (ja) 2021-06-24
JP6502428B2 (ja) 2019-04-17
US20140178355A1 (en) 2014-06-26
CA2882502A1 (en) 2013-02-14
US9925249B2 (en) 2018-03-27
WO2013023151A3 (en) 2013-07-18
JP6342802B2 (ja) 2018-06-13
US20210085761A1 (en) 2021-03-25
RS57234B1 (sr) 2018-07-31
US9289473B2 (en) 2016-03-22
NO2718434T3 (show.php) 2018-08-25
EP4023243A3 (en) 2022-09-14
SMT201800249T1 (it) 2018-07-17
ES2896489T3 (es) 2022-02-24
PL2718434T3 (pl) 2018-08-31
JP2024028452A (ja) 2024-03-04
HUE037870T2 (hu) 2018-09-28
JP2017221201A (ja) 2017-12-21
CY1120877T1 (el) 2019-12-11
US20160166656A1 (en) 2016-06-16
EP3400958B1 (en) 2021-08-04
PL3400958T3 (pl) 2022-01-03
EP4023243A2 (en) 2022-07-06
JP2019162107A (ja) 2019-09-26
US10149892B2 (en) 2018-12-11
US20180185458A1 (en) 2018-07-05
US10874720B2 (en) 2020-12-29
US20190083585A1 (en) 2019-03-21
WO2013023151A2 (en) 2013-02-14
EP3400958A1 (en) 2018-11-14
US12544430B2 (en) 2026-02-10
US20240207376A1 (en) 2024-06-27
EP2718434A2 (en) 2014-04-16
DK2718434T3 (en) 2018-07-09
TR201806885T4 (tr) 2018-06-21
US20170296633A1 (en) 2017-10-19
JP2014529399A (ja) 2014-11-13
US9707280B2 (en) 2017-07-18
HRP20180687T1 (hr) 2018-06-15
ES2667418T3 (es) 2018-05-10
EP2718434B1 (en) 2018-03-28
LT2718434T (lt) 2018-08-10
PT2718434T (pt) 2018-05-21

Similar Documents

Publication Publication Date Title
SI2718434T1 (en) Compositions and methods for treating celiac sprue disease
NZ602943A (en) Modified binding proteins inhibiting the vegf-a receptor interaction
NZ587105A (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
HRP20192314T1 (hr) Pripravci faktora viii i postupci pripreme i njihove uporabe
EA201692359A1 (ru) Композиция на основе нового штамма prrsv или его белков, продукт, их применение, вирус prrsv, выделенная нк и рекомбинантный вектор экспрессии для получения этого вируса
JP2015134796A5 (show.php)
PH12013501865A1 (en) Potent and selective inhibitors of nav1.3 and nav1.7
NZ604818A (en) Variants of activin iib receptor polypeptides and uses thereof
ZA202302340B (en) Compositions and methods for treating celiac sprue disease
MX2010005783A (es) Secuencias de aminoacidos dirigidas contra citoquinas heterodimericas y/o sus receptores y polipeptidos que comprenden las mismas.
NZ621868A (en) Growth hormone polypeptides and methods of making and using same
IN2014DN09963A (show.php)
JP2014529399A5 (show.php)
SI3079715T1 (en) A mixture of peptides
NZ750559A (en) Complete genome sequence of the methanogen methanobrevibacter ruminantium
TW201129379A (en) Anti-Orai1 antigen binding proteins and uses thereof
JP2017221201A5 (show.php)
JP2015510393A5 (show.php)
MX391136B (es) FRAGMENTOS DE OspA ESTABILIZADOS CON CISTEÍNA Y MÉTODO DE USO
NZ708990A (en) Method for activating helper t cell
WO2009024327A3 (en) New proteins for use in human and animal staphylococcus infections
RU2015112625A (ru) Пептид, применение пептида для лечения сердечно-сосудистых заболеваний, нуклеотидная последовательность, вектор экспрессии, хозяйская клетка, фармацевтическая композиция
RU2015119523A (ru) Новый способ лечения повреждения спинного мозга с применением фрагмента hmgb1
SG10201407944TA (en) Imp-3 oligopeptides and vaccines including the same
NZ609474A (en) Fviii peptides for immune tolerance induction and immunodiagnostics